Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.’ The study aims to evaluate the safety and immune response of a second dose of the RSVpreF vaccine in pregnant participants and assess the duration of immunity from a single dose administered during a previous pregnancy. This research is significant for enhancing maternal and infant health through improved vaccination strategies.
The study tests the RSVpreF vaccine, a biological intervention designed to prevent RSV infections. Participants in the study receive either the RSVpreF vaccine or a placebo to compare the outcomes effectively.
This interventional study employs a randomized, parallel assignment model with quadruple masking for participants, care providers, investigators, and outcomes assessors. The primary purpose is prevention, focusing on the safety and efficacy of the vaccine during pregnancy.
The study began on April 16, 2025, with primary completion expected to follow. The latest update was submitted on July 16, 2025, indicating ongoing recruitment and progress in the study.
The outcome of this study could significantly impact Pfizer’s stock performance by potentially strengthening its position in the vaccine market, especially if the results show enhanced safety and efficacy. Competitors in the RSV vaccine space may feel increased pressure to innovate and improve their offerings.
The study is currently ongoing, with further details available on the ClinicalTrials portal.